This peptide blend is discussed as a combination of a synthetic gastric-derived peptide fragment and a thymosin beta peptide analogue
In relation to NO-system, stable pentadecapeptide BPC 157 counteracts lidocaine-induced adverse effects in rats and depolarisation in vitro
Its commonly used in clinical settings to dilute medications for intramuscular, subcutaneous, and intravenous injection, including certain hormones, vitamins, and other injectable compounds
Inject the full dose slowly and steadily
It also promotes the production of other healing proteins in the body
Peptide AOD 9604 therapy has been gaining traction in the medical and wellness communities for it use as a support for fat loss, improving metabolic function, and activating recovery without most of the risks of other hormonal agents